Åse Bratland

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

Geeta Gulati, Siri Lagethon Heck, Anne Hansen Ree et al. · European Heart Journal · 2016 · 685 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington, Barbara Burtness, Richard Greil et al. · Journal of Clinical Oncology · 2022 · 490 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by Programmed Death Ligand-1 combined positive score

Barbara Burtness, Danny Rischin, Richard Greil et al. · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · 2022 · 177 citations

Medicine, Oncology, Pharmacotherapy +17

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Danny Rischin, Kevin J. Harrington, Richard Greil et al. · Journal of Clinical Oncology · 2019 · 132 citations

Medicine, Oncology, Pharmacology +14